Hamvas Aaron
Edward Mallinckrodt Department of Pediatrics, Washington University and St. Louis Children's Hospital, St. Louis, MO 63110, USA.
Semin Perinatol. 2006 Dec;30(6):316-26. doi: 10.1053/j.semperi.2005.11.002.
The pulmonary surfactant is a mixture of phospholipids and proteins synthesized, packaged, and secreted by alveolar type II cells that lowers surface tension and prevents atelectasis at end-expiration. A tightly regulated, complex metabolic cycle involves all components of the pulmonary surfactant. Disorders of surfactant metabolism that have a genetic basis are rare, but causes of respiratory dysfunction in infants and children emerge. Recessive loss of function mutations in surfactant protein-B (SP-B) gene lead to respiratory failure that is lethal in the newborn period while single allelic mutations in the surfactant protein-C (SP-C) gene cause interstitial lung disease of varying severity and age of onset. The genetic basis, mechanisms, clinical presentation and outcome, diagnostic approach and limited therapeutic options for disease due to mutations the SP-B and SP-C genes will be described in detail in this article. These disorders provide insights into some of the distinct mechanisms that disrupt the surfactant metabolic cycle and cause respiratory disease in infants and children.
肺表面活性物质是一种由II型肺泡细胞合成、包装和分泌的磷脂与蛋白质的混合物,它能降低表面张力并防止呼气末肺不张。一个受到严格调控的复杂代谢循环涉及肺表面活性物质的所有成分。具有遗传基础的表面活性物质代谢紊乱较为罕见,但婴儿和儿童呼吸功能障碍的病因却不断出现。表面活性蛋白-B(SP-B)基因的隐性功能丧失突变会导致呼吸衰竭,在新生儿期具有致死性,而表面活性蛋白-C(SP-C)基因的单等位基因突变会导致严重程度和发病年龄各异的间质性肺病。本文将详细描述因SP-B和SP-C基因突变所致疾病的遗传基础、机制、临床表现及转归、诊断方法和有限的治疗选择。这些疾病为扰乱表面活性物质代谢循环并导致婴幼儿呼吸系统疾病的一些独特机制提供了见解。